Symbols / PACB Stock $1.31 -2.96% Pacific Biosciences of California, Inc.

Healthcare • Medical Devices • United States • NMS
PACB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Christian O. Henry M.B.A.
Exch · Country NMS · United States
Market Cap 406.89M
Enterprise Value 837.31M
Income -128.58M
Sales 160.03M
FCF (ttm) -48.24M
Book/sh 0.01
Cash/sh 0.89
Employees 485
Insider 10d —
IPO Oct 27, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.30
PEG —
P/S 2.54
P/B 163.75
P/C —
EV/EBITDA -5.85
EV/Sales 5.23
Quick Ratio 4.67
Current Ratio 5.65
Debt/Eq 29,855.79
LT Debt/Eq —
EPS (ttm) -0.41
EPS next Y -0.40
EPS Growth —
Revenue Growth 0.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -11.96%
ROE -273.55%
ROIC —
Gross Margin 38.33%
Oper. Margin -102.89%
Profit Margin -80.34%
Shs Outstand 310.60M
Shs Float 303.44M
Insider Own 8.77%
Instit Own 54.01%
Short Float 18.03%
Short Ratio 7.88
Short Interest 48.71M
52W High 2.73
vs 52W High -52.01%
52W Low 1.09
vs 52W Low 20.18%
Beta 2.32
Impl. Vol. 3.16%
Rel Volume 0.82
Avg Volume 6.04M
Volume 4.97M
Target (mean) $2.46
Tgt Median $2.62
Tgt Low $1.50
Tgt High $3.00
# Analysts 6
Recom Buy
Prev Close $1.35
Price $1.31
Change -2.96%
About

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.46
Mean price target
2. Current target
$1.31
Latest analyst target
3. DCF / Fair value
$-2.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.31
Low
$1.50
High
$3.00
Mean
$2.46

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-11 main Barclays Underweight → Underweight $2
2026-04-14 main Barclays Underweight → Underweight $1
2026-03-06 down Barclays Equal-Weight → Underweight $2
2025-12-15 main Barclays Equal-Weight → Equal-Weight $2
2025-11-11 main Piper Sandler Neutral → Neutral $2
2025-11-10 main Stephens & Co. Overweight → Overweight $2
2025-08-11 main Piper Sandler Neutral → Neutral $2
2025-06-25 main Barclays Equal-Weight → Equal-Weight $2
2025-05-15 main Piper Sandler Neutral → Neutral $1
2025-05-15 reit Stephens & Co. Overweight → Overweight $2
2025-04-10 main Canaccord Genuity Buy → Buy $3
2025-03-25 main Scotiabank Sector Outperform → Sector Outperform $2
2025-02-20 reit Piper Sandler Neutral → Neutral $2
2025-02-18 main Goldman Sachs Neutral → Neutral $2
2025-02-18 reit Stephens & Co. Overweight → Overweight $3
2025-02-14 reit Stephens & Co. Overweight → Overweight $3
2025-01-23 main Goldman Sachs Neutral → Neutral $2
2024-11-11 down UBS Buy → Neutral $2
2024-11-11 main Scotiabank Sector Outperform → Sector Outperform $6
2024-11-11 main Piper Sandler Neutral → Neutral $3
News
RSS: Latest PACB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-08 GIBSON CHRISTOPHER Director — 57,473 $0.00 $0
2026-04-01 GIBSON JAMES R II Chief Financial Officer — 88,185 $1.37 $120,813
2026-03-03 VAN OENE MARK D Chief Operating Officer — 6,504 $1.51 $9,847
2026-03-03 FARMER MICHELE CPA Officer — 2,979 $1.51 $4,510
2026-03-03 HENRY CHRISTIAN O Chief Executive Officer — 12,497 $1.51 $18,920
2026-03-03 GIBSON CHRISTOPHER Director — 53,913 $0.00 $0
2026-02-27 VAN OENE MARK D Chief Operating Officer — 500,000 $0.00 $0
2026-02-27 FARMER MICHELE CPA Officer — 89,835 $0.00 $0
2026-02-27 HENRY CHRISTIAN O Chief Executive Officer — 920,810 $0.00 $0
2026-02-27 GIBSON JAMES R II Chief Financial Officer — 333,848 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
160.00
+3.89%
154.01
-23.19%
200.52
+56.29%
128.30
Operating Revenue
160.00
+3.89%
154.01
-23.19%
200.52
+56.29%
128.30
Cost Of Revenue
114.22
-2.15%
116.73
-20.99%
147.74
+86.38%
79.27
Reconciled Cost Of Revenue
92.35
+13.48%
81.39
-36.10%
127.36
+105.59%
61.95
Gross Profit
45.78
+22.79%
37.28
-29.36%
52.78
+7.64%
49.03
Operating Expense
603.34
+83.98%
327.94
-9.69%
363.14
+2.63%
353.85
Research And Development
97.31
-27.88%
134.92
-27.91%
187.17
-3.02%
193.00
Selling General And Administration
141.49
-19.15%
175.02
+3.06%
169.82
+5.57%
160.85
Total Expenses
717.57
+61.37%
444.68
-12.96%
510.89
+17.95%
433.12
Operating Income
-557.56
-91.82%
-290.66
+6.35%
-310.37
-1.82%
-304.82
Total Operating Income As Reported
-553.86
-16.77%
-474.31
-41.81%
-334.47
-8.88%
-307.20
EBITDA
-152.69
+37.10%
-242.77
+12.45%
-277.28
+1.76%
-282.24
Normalized EBITDA
-156.39
+26.76%
-213.53
+14.98%
-251.15
+10.26%
-279.86
Reconciled Depreciation
386.41
+624.28%
53.35
+101.07%
26.53
+53.22%
17.32
EBIT
-539.10
-82.05%
-296.12
+2.53%
-303.82
-1.42%
-299.56
Total Unusual Items
3.70
+112.65%
-29.24
-11.89%
-26.14
-999.50%
-2.38
Total Unusual Items Excluding Goodwill
3.70
+112.65%
-29.24
-11.89%
-26.14
-999.50%
-2.38
Special Income Charges
3.70
+112.65%
-29.24
-11.89%
-26.14
-999.50%
-2.38
Other Special Charges
—
-154.41
-7695.03%
2.03
—
Restructuring And Mergern Acquisition
-18.70
-2100.00%
-0.85
-103.53%
24.10
+913.97%
2.38
Write Off
15.00
-91.87%
184.50
0.00
0.00
Net Income
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Pretax Income
-546.06
-76.41%
-309.54
+2.71%
-318.16
-1.24%
-314.25
Net Non Operating Interest Income Expense
-6.95
+48.15%
-13.41
+6.49%
-14.34
+2.36%
-14.69
Interest Expense Non Operating
6.95
-48.15%
13.41
-6.49%
14.34
-2.36%
14.69
Net Interest Income
-6.95
+48.15%
-13.41
+6.49%
-14.34
+2.36%
-14.69
Interest Expense
6.95
-48.15%
13.41
-6.49%
14.34
-2.36%
14.69
Other Income Expense
18.46
+438.04%
-5.46
-183.37%
6.55
+24.48%
5.26
Other Non Operating Income Expenses
14.76
-37.95%
23.78
-27.23%
32.68
+327.91%
7.64
Tax Provision
0.32
+0.63%
0.32
+102.77%
-11.42
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+483.33%
0.00
+3500.00%
0.00
Tax Effect Of Unusual Items
0.78
+112.65%
-6.14
-552.70%
-0.94
-39481.83%
-0.00
Net Income Including Noncontrolling Interests
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Net Income From Continuing Operation Net Minority Interest
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Net Income From Continuing And Discontinued Operation
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Net Income Continuous Operations
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Normalized Income
-549.30
-91.56%
-286.75
-1.85%
-281.54
+9.73%
-311.87
Net Income Common Stockholders
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Diluted EPS
-1.82
-15.19%
-1.58
-30.58%
-1.21
+13.57%
-1.40
Basic EPS
-1.82
-62.50%
-1.12
+7.44%
-1.21
+13.57%
-1.40
Basic Average Shares
299.96
+9.28%
274.49
+8.22%
253.63
+12.95%
224.55
Diluted Average Shares
299.96
+4.02%
288.37
+13.70%
253.63
+12.95%
224.55
Diluted NI Availto Com Stockholders
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Amortization
364.54
+1924.55%
18.01
+192.45%
6.16
0.00
Amortization Of Intangibles Income Statement
364.54
+1924.55%
18.01
+192.45%
6.16
0.00
Depreciation Amortization Depletion Income Statement
364.54
+1924.55%
18.01
+192.45%
6.16
0.00
Depreciation And Amortization In Income Statement
364.54
+1924.55%
18.01
+192.45%
6.16
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
784.08
-37.79%
1,260.45
-27.81%
1,746.01
-1.19%
1,767.09
Current Assets
375.05
-24.34%
495.68
-33.20%
742.05
-12.91%
852.07
Cash Cash Equivalents And Short Term Investments
279.51
-28.32%
389.93
-38.24%
631.42
-18.24%
772.32
Cash And Cash Equivalents
63.71
+15.06%
55.37
-69.22%
179.91
-44.66%
325.09
Cash Equivalents
3.21
0.00
-100.00%
109.74
-41.46%
187.45
Cash Financial
60.50
+9.26%
55.37
-21.09%
70.17
-49.02%
137.64
Other Short Term Investments
215.80
-35.50%
334.56
-25.90%
451.50
+0.96%
447.23
Receivables
35.45
+28.79%
27.52
-24.83%
36.62
+94.91%
18.79
Accounts Receivable
35.45
+28.79%
27.52
-24.83%
36.62
+94.91%
18.79
Inventory
49.28
-16.12%
58.76
+3.67%
56.68
+12.49%
50.38
Raw Materials
38.64
-14.65%
45.27
+39.58%
32.43
+34.36%
24.14
Work In Process
27.05
+22.01%
22.17
-19.82%
27.65
+96.65%
14.06
Finished Goods
15.71
+11.56%
14.08
-10.57%
15.75
+29.28%
12.18
Prepaid Assets
—
—
—
10.29
Restricted Cash
0.02
-97.10%
0.69
+130.00%
0.30
+0.00%
0.30
Other Current Assets
10.79
-42.53%
18.78
+10.22%
17.04
+65.61%
10.29
Total Non Current Assets
409.03
-46.52%
764.77
-23.83%
1,003.97
+9.72%
915.01
Net PPE
65.84
+41.30%
46.60
-32.49%
69.03
-15.14%
81.34
Gross PPE
158.31
+23.16%
128.54
-10.62%
143.82
-1.72%
146.33
Accumulated Depreciation
-92.47
-12.84%
-81.95
-9.56%
-74.79
-15.09%
-64.99
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
77.37
+1.26%
76.41
+2.34%
74.66
+10.21%
67.74
Construction In Progress
5.41
+137.65%
2.28
+69.47%
1.34
-71.41%
4.70
Other Properties
41.70
+159.12%
16.09
-50.63%
32.59
-18.03%
39.76
Leases
33.84
+0.20%
33.77
-4.13%
35.23
+3.21%
34.13
Goodwill And Other Intangible Assets
332.88
-52.94%
707.33
-23.05%
919.25
+12.07%
820.22
Goodwill
317.76
+0.00%
317.76
-31.26%
462.26
+12.75%
409.97
Other Intangible Assets
15.12
-96.12%
389.57
-14.75%
456.98
+11.39%
410.25
Other Non Current Assets
10.30
-4.91%
10.84
-30.96%
15.70
+16.70%
13.45
Total Liabilities Net Minority Interest
778.73
+3.30%
753.85
-27.84%
1,044.71
-13.24%
1,204.18
Current Liabilities
72.83
+9.85%
66.30
-30.23%
95.03
-63.91%
263.33
Payables And Accrued Expenses
54.42
+38.87%
39.19
-35.52%
60.77
+36.18%
44.62
Payables
20.77
+25.20%
16.59
+10.14%
15.06
+25.22%
12.03
Accounts Payable
20.77
+25.20%
16.59
+10.14%
15.06
+25.22%
12.03
Current Accrued Expenses
33.65
+48.91%
22.59
-50.57%
45.71
+40.23%
32.60
Pensionand Other Post Retirement Benefit Plans Current
1.38
-31.63%
2.01
-45.79%
3.71
+2.12%
3.64
Current Debt And Capital Lease Obligation
0.45
-95.53%
10.03
-0.55%
10.08
-6.03%
10.73
Current Debt
—
—
0.49
-73.40%
1.84
Other Current Borrowings
—
—
0.49
-73.40%
1.84
Current Capital Lease Obligation
0.45
-95.53%
10.03
+4.54%
9.59
+7.93%
8.89
Current Deferred Liabilities
15.94
+14.95%
13.86
-15.16%
16.34
-46.42%
30.50
Current Deferred Revenue
15.94
+14.95%
13.86
-15.16%
16.34
-46.42%
30.50
Other Current Liabilities
0.65
-45.95%
1.21
-70.64%
4.12
-97.63%
173.85
Total Non Current Liabilities Net Minority Interest
705.90
+2.67%
687.55
-27.60%
949.68
+0.94%
940.85
Long Term Debt And Capital Lease Obligation
701.97
+5.97%
662.41
-28.30%
923.85
-1.48%
937.75
Long Term Debt
645.38
-0.33%
647.49
-27.43%
892.24
-0.50%
896.68
Long Term Capital Lease Obligation
56.59
+279.46%
14.91
-52.81%
31.61
-23.04%
41.07
Non Current Deferred Liabilities
3.93
-33.41%
5.90
+6.69%
5.53
+208.25%
1.79
Non Current Deferred Revenue
3.93
-33.41%
5.90
+6.69%
5.53
+208.25%
1.79
Other Non Current Liabilities
—
19.25
-5.20%
20.30
+1461.62%
1.30
Stockholders Equity
5.35
-98.94%
506.59
-27.76%
701.30
+24.59%
562.90
Common Stock Equity
5.35
-98.94%
506.59
-27.76%
701.30
+24.59%
562.90
Capital Stock
0.30
+2.72%
0.29
+9.70%
0.27
+18.06%
0.23
Common Stock
0.30
+2.72%
0.29
+9.70%
0.27
+18.06%
0.23
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
301.96
+2.56%
294.42
+9.96%
267.74
+18.21%
226.50
Ordinary Shares Number
301.96
+2.56%
294.42
+9.96%
267.74
+18.21%
226.50
Additional Paid In Capital
2,699.89
+1.70%
2,654.80
+4.52%
2,539.89
+20.96%
2,099.78
Retained Earnings
-2,695.30
-25.43%
-2,148.93
-16.85%
-1,839.08
-20.02%
-1,532.34
Gains Losses Not Affecting Retained Earnings
0.46
+8.29%
0.42
+92.69%
0.22
+104.60%
-4.76
Other Equity Adjustments
0.46
+8.29%
0.42
+92.69%
0.22
+104.60%
-4.76
Total Equity Gross Minority Interest
5.35
-98.94%
506.59
-27.76%
701.30
+24.59%
562.90
Total Capitalization
650.73
-43.62%
1,154.09
-27.58%
1,593.55
+9.18%
1,459.59
Working Capital
302.22
-29.61%
429.38
-33.64%
647.02
+9.90%
588.74
Invested Capital
650.73
-43.62%
1,154.09
-27.60%
1,594.04
+9.07%
1,461.43
Total Debt
702.42
+4.46%
672.43
-28.00%
933.93
-1.53%
948.48
Net Debt
581.67
-1.76%
592.12
-16.93%
712.82
+24.31%
573.44
Capital Lease Obligations
57.04
+128.71%
24.94
-39.46%
41.20
-17.53%
49.96
Net Tangible Assets
-327.54
-63.17%
-200.74
+7.89%
-217.94
+15.30%
-257.31
Tangible Book Value
-327.54
-63.17%
-200.74
+7.89%
-217.94
+15.30%
-257.31
Interest Payable
3.27
+32.39%
2.47
-12.84%
2.83
-44.43%
5.10
Inventories Adjustments Allowances
-32.11
-41.04%
-22.77
-18.85%
-19.16
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-111.21
+46.03%
-206.06
+20.49%
-259.17
+1.53%
-263.21
Cash Flow From Continuing Operating Activities
-111.21
+46.03%
-206.06
+20.49%
-259.17
+1.53%
-263.21
Net Income From Continuing Operations
-546.38
-76.34%
-309.85
-1.02%
-306.74
+2.39%
-314.25
Depreciation Amortization Depletion
386.41
+624.28%
53.35
+101.07%
26.53
+53.22%
17.32
Depreciation
16.96
-34.60%
25.94
+41.95%
18.27
+11.39%
16.41
Amortization Cash Flow
369.45
+1247.76%
27.41
+231.82%
8.26
+804.82%
0.91
Depreciation And Amortization
386.41
+624.28%
53.35
+101.07%
26.53
+53.22%
17.32
Amortization Of Intangibles
369.45
+1247.76%
27.41
+231.82%
8.26
+804.82%
0.91
Other Non Cash Items
-17.01
+89.09%
-155.88
-898.84%
19.51
+492.23%
3.29
Stock Based Compensation
41.67
-41.34%
71.04
-1.50%
72.12
-8.26%
78.61
Provisionand Write Offof Assets
9.57
+107.19%
4.62
-56.37%
10.58
+75.61%
6.03
Asset Impairment Charge
15.00
-91.87%
184.50
0.00
0.00
Deferred Tax
-0.55
-166.34%
-0.20
+98.21%
-11.42
0.00
Deferred Income Tax
-0.55
-166.34%
-0.20
+98.21%
-11.42
0.00
Operating Gains Losses
—
—
2.03
+631.29%
0.28
Gain Loss On Sale Of PPE
—
—
—
0.28
Change In Working Capital
4.44
+110.95%
-40.58
+31.17%
-58.96
-9.24%
-53.97
Change In Receivables
-7.92
-187.16%
9.09
+150.99%
-17.83
-426.84%
5.46
Changes In Account Receivables
-7.92
-187.16%
9.09
+150.99%
-17.83
-426.84%
5.46
Change In Inventory
-1.42
+82.94%
-8.32
+39.89%
-13.84
+59.18%
-33.91
Change In Prepaid Assets
8.51
+282.14%
2.23
+124.80%
-8.98
+27.10%
-12.32
Change In Payables And Accrued Expense
5.64
+122.62%
-24.94
-287.37%
13.31
+606.82%
-2.63
Change In Accrued Expense
3.16
+111.99%
-26.34
-301.04%
13.10
+458.89%
-3.65
Change In Payable
2.48
+76.65%
1.41
+582.04%
0.21
-79.90%
1.02
Change In Account Payable
2.48
+76.65%
1.41
+582.04%
0.21
-79.90%
1.02
Change In Other Working Capital
0.10
+104.79%
-2.11
+79.77%
-10.42
-179.06%
-3.73
Change In Other Current Liabilities
-0.47
+97.16%
-16.53
+21.99%
-21.19
-209.96%
-6.84
Investing Cash Flow
115.45
-6.90%
124.00
+2593.40%
4.60
-96.03%
116.08
Cash Flow From Continuing Investing Activities
115.45
-6.90%
124.00
+2593.40%
4.60
-96.03%
116.08
Net PPE Purchase And Sale
-2.71
+56.14%
-6.19
+30.02%
-8.84
+47.21%
-16.75
Purchase Of PPE
-2.71
+56.14%
-6.19
+30.02%
-8.84
+47.21%
-16.75
Capital Expenditure
-7.71
-24.66%
-6.19
+30.02%
-8.84
+47.76%
-16.93
Net Investment Purchase And Sale
123.16
-5.40%
130.19
+860.90%
13.55
-89.81%
133.01
Purchase Of Investment
-216.91
+56.50%
-498.63
+34.09%
-756.57
-70.86%
-442.79
Sale Of Investment
340.07
-45.92%
628.83
-18.35%
770.12
+33.75%
575.80
Net Business Purchase And Sale
0.00
0.00
+100.00%
-0.10
0.00
Purchase Of Business
0.00
0.00
+100.00%
-0.10
0.00
Net Intangibles Purchase And Sale
-5.00
0.00
0.00
+100.00%
-0.18
Purchase Of Intangibles
-5.00
0.00
0.00
+100.00%
-0.18
Financing Cash Flow
3.43
+107.97%
-42.99
-139.48%
108.89
+1031.69%
9.62
Cash Flow From Continuing Financing Activities
3.43
+107.97%
-42.99
-139.48%
108.89
+1031.69%
9.62
Net Issuance Payments Of Debt
0.00
+100.00%
-0.49
+73.40%
-1.84
-14.55%
-1.61
Issuance Of Debt
—
—
0.00
0.00
Repayment Of Debt
0.00
+100.00%
-0.49
+73.40%
-1.84
-14.55%
-1.61
Long Term Debt Issuance
—
—
0.00
0.00
Long Term Debt Payments
0.00
+100.00%
-0.49
+73.40%
-1.84
-14.55%
-1.61
Net Long Term Debt Issuance
0.00
+100.00%
-0.49
+73.40%
-1.84
-14.55%
-1.61
Net Common Stock Issuance
0.00
0.00
-100.00%
189.20
0.00
Proceeds From Stock Option Exercised
3.43
-55.50%
7.70
-49.72%
15.32
+36.41%
11.23
Net Other Financing Charges
—
-50.20
+46.47%
-93.79
—
Changes In Cash
7.67
+106.13%
-125.04
+14.17%
-145.68
-5.94%
-137.51
Beginning Cash Position
57.59
-68.47%
182.63
-44.37%
328.31
-29.52%
465.82
End Cash Position
65.26
+13.31%
57.59
-68.47%
182.63
-43.82%
325.09
Free Cash Flow
-118.92
+43.97%
-212.25
+20.81%
-268.02
+4.33%
-280.14
Interest Paid Supplemental Data
8.26
-44.18%
14.80
-5.62%
15.69
+11.66%
14.05
Amortization Of Securities
-4.37
+66.54%
-13.04
-1.59%
-12.84
-5162.30%
-0.24
Common Stock Issuance
0.00
0.00
-100.00%
189.20
0.00
Issuance Of Capital Stock
0.00
0.00
-100.00%
189.20
0.00
Other Cash Adjustment Outside Changein Cash
—
-2.22
+18.37%
-2.72
+15.52%
-3.22
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category